Bimatoprost (Lumigan)
San Francisco, CA

You may qualify to participate in a clinical research study involving the investigational use of bimatoprost (Lumigan) ophthalmic drops in promoting eyelash growth in patients with eyelash loss due to alopecia areata. Bimatatoprost ophthalmic solution is approved for the treatment of glaucoma. Patients who are treated fro glaucoma with this medication often notice longer, thicker eyelashes. Currently there are no safe or acceptable treatments for eyelash loss due to alopecia areata.

You may qualify to participate in this study if you:
-Are between the ages of 18-70
-Have 50% or more eyelash loss in both eyes due to alopecia areata which has been present for 6 months or longer.

All office visits, ophthalmologic examinations, photographs, and study drug will be provided without charge. There is no compensation for time or travel. If you live in the vicinity of the location listed below and would like to find out if you qualify to be a participant, or if you have further questions about this study, please call the investigator below.

Investigator:
Vera H. Price MD
Location: University of California, San Francisco
Contact: Blanca E. Ochoa, MD, 415-353-9529, hair@derm.ucsf.edu

Kenalog-10
Minneapolis, MN

Dr. Maria Hordinsky and Joanna Quast, Student Pharmacist (The University of Minnesota, Minneapolis, MN) are conducting a study examining the relationship between a commonly utilized treatment for alopecia areata, Kenalog-10 intralesional injections, and its effect on the function of the adrenal glands. This study will also look to evaluate the efficacy of this treatment on hair regrowth.

Otherwise healthy patients diagnosed with alopecia areata for at least 3, but not more than 24, months will be eligible for enrollment in this study. Those enrolled will undergo intralesional Kenalog-10 (triamcinolone acetonide10mg/mL) injections every 6 weeks for a period of 6 months. This period will be followed by a 6 and 12-week, injection-free, follow-up visit. Detection of adrenal insufficiency will be observed with use of the Low Dose Adrenocorticotropic Hormone Stimulation Test at each patient treatment visit. This study will provide the first comprehensive review of the effect of intralesional Kenalog 10 injections on adrenal gland function in patients receiving this therapy for alopecia areata. This study will advance the understanding of the safety of this highly utilized therapy. For more information or if you would like to be involved, please contact the University of Minnesota Department of Dermatology:

Cathy Boeck
612-625-4973
boeck001@umn.edu

Disclaimer:
NAAF provides research notices as an informational service to its members. This information does not represent a NAAF endorsement, but rather makes you aware that clinical studies are available for your participation if you choose. If you are presently under the care of a physician for alopecia areata, or other conditions, you should discuss this study with your doctor before altering your treatment program.